Official EU label nameGlossary entry 28210

TAFLUPROST

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 1 of 13 indexed market datasets: 1 country records and 0 EU Annex records. Every result and evidence gap is listed below.

1 markets with evidence
Markets checked
13
Markets with evidence
1
Evidence gaps
12
Resolved identifiers
15

A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.

Resolved substance identity

CAS:209860-87-7745-65-3155206-00-140665-92-7363-24-635121-78-940666-16-8130209-82-459122-46-2157283-68-681846-19-7120373-36-6130209-76-61005193-64-5157283-66-4
Ingredient index records:
TAFLUPROST
Cosmetic functions: HAIR CONDITIONING

Isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1- enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate

3 matched or reported names
TAFLUPROSTtafluprostProstaglandins, their salts and derivatives and their analogs

Regulatory evidence in all 13 markets

Open each matched record for its scope, concentration, conditions, warnings and official source version.

Swipe or scroll horizontally to see dataset coverage and next actions.

MarketResultRecordsDatasetMeaning / next action
European Union
EU
No local match0
Complete annex dataset
Regulation (EC) 1223/2009 consolidated to 1 May 2026
No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain
GB
No local match0
Complete consolidated annex dataset
GB retained Regulation 1223/2009 schedules, effective 15 August 2026
No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.
Canada
CA
Prohibited1Open record 1
Complete Hotlist snapshot
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025
Review every linked record and exact conditions.
New Zealand
NZ
No local match0
Complete schedules dataset
Cosmetic Products Group Standard schedules effective 1 January 2026
The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
ASEAN
ASEAN
No local match0
Complete regional annex dataset
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
China
CN
No local match0
Complete prohibited catalogues plus official-source workflow
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025
IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately.
Japan
JP
No local match0
Complete Standards appendices dataset
MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot
The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion.
South Korea
KR
No local match0
Complete current appendix dataset
MFDS Notice 2026-19, effective 18 March 2026
Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
United States
US
No local match0
Complete enumerated federal ingredient rules
eCFR Title 21 issue date 27 August 2026
FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia
AU
No local match0
Complete cosmetic-relevant Poisons Standard subset plus official workflow
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026
An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil
BR
No local match0
Complete prohibited dataset plus current restricted-list workflow
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
India
IN
No local match0
Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)
The standards are separate controlled publications; absence from a locally indexed excerpt is not permission.
Saudi Arabia
SA
No local match0
Complete official list index
SFDA live prohibited/restricted lists, snapshot 30 August 2026
No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.
No market rows match this filter.

Matching market records and conditions

Chemical identity and properties

PubChem 2D chemical structure for CAS 1005193-64-5
CAS 1005193-64-5PubChem CID 50940350

TrifluoroMethyl Dechloro

IUPAC name
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
Molecular formula
C25H34F3NO5
Molecular weight
485.5 g/mol
Exact mass
485.23890767 Da
XLogP3
3.0
Topological polar surface area
99.0 Ų
Hydrogen-bond donors
4
Hydrogen-bond acceptors
8
Covalent units
1
Defined stereocentres
5

Also known as

N-Ethyl Fluprostenol Carboxamide(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-N-ethyl-5-heptenamideTrifluoroMethylDechloroC25H34F3NO5Trifluoromethyl Dechloro Ethylcloprostenolamide(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match50940350

Attributed physical-property, hazard, environmental and use annotations.

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
EMBL-EBI ChEBINo exact record2026-08-31
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 120373-36-6
CAS 120373-36-6PubChem CID 5311236

Unoprostone

IUPAC name
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid
Molecular formula
C22H38O5
Molecular weight
382.5 g/mol
Exact mass
382.27192431 Da
XLogP3
3.7
Topological polar surface area
94.8 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
4

Also known as

unoprostona13,14-dihydro-15-keto-20-ethyl PGF2alpha6X4F561V3W(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acidCHEBI:39455(+)-(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)-5-heptenoic acid9,11-dihydroxy-15-oxo-20a,20b-dihomoprost-5Z-en-1-oic acid(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)hept-5-enoic acid
16 more reported names
unoprostonumRefChem:1100656S01EE02Unoprostone [MI]Unoprostone [INN]UnoprostaneUnoprostone (INN)13,14-Dihydro-15-keto-20-ethyl prostaglandin f2alphaUNII-6X4F561V3WUNOPROSTONE [VANDF]UNOPROSTONE [WHO-DD]HMS3648D22EBC-26874DA-68484HY-106916CS-0026907
External database identifiers

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match5311236

Attributed physical-property, hazard, environmental and use annotations.

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 130209-76-6
CAS 130209-76-6PubChem CID 5283107

17-phenyl-trinor-PGF2alpha isopropyl ester

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]hept-5-enoate
Molecular formula
C26H38O5
Molecular weight
430.6 g/mol
Exact mass
430.27192431 Da
XLogP3
3.8
Topological polar surface area
87.0 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
5

Also known as

isopropyl 9S,11R,15S-trihydroxy-17-phenyl-18,19,20-trinor-5Z,13E-prostadienoateRefChem:1057638Bimatoprost isopropyl ester17-Phenyl trinor Pgf2alpha-IprdehydrolatanoprostPhDH 100A1IFH52MD8T17-Phenyl trinor PGF2|A isopropyl ester
16 more reported names
17-Phenyl-18,19,20-trinor-pgf2alpha-1-isopropyl ester17-phenyl trinor PGF2alpha isopropyl esterisopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)hept-5-enoatePhdh100A5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-, 1-methylethyl ester, (5Z)-UNII-1IFH52MD8TBimatoprost Acid Isopropyl Ester5-HEPTENOIC ACID, 7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3S)-3-HYDROXY-5-PHENYL-1-PENTEN-1-YL)CYCLOPENTYL)-, 1-METHYLETHYL ESTER, (5Z)-PGF2Alpha,17-phenylCHEBI:137717JGZRPRSJSQLFBO-FWPUOYPASA-NHMS3648J1817-Phenyl-18,19,20-trinor-prostaglandin F2alpha-1-isopropyl esterFA 26:7;O3HY-116161A(1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-1-Methylethyl 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-5-heptenoate
External database identifiers

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match5283107

Attributed physical-property, hazard, environmental and use annotations.

  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302+H312+H332 (100%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]; H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H312 (100%): Harmful in contact with skin [Warning Acute toxicity, dermal]; H332 (100%): Harmful if inhaled [Warning Acute toxicity, inhalation]; H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. Source: European Chemicals Agency (ECHA)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 130209-82-4
CAS 130209-82-4PubChem CID 5311221

Latanoprost

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
Molecular formula
C26H40O5
Molecular weight
432.6 g/mol
Exact mass
432.28757437 Da
XLogP3
4.3
Topological polar surface area
87.0 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
5

Also known as

XalatanPhXA41PHXA-41XA41PhXA 41XA-41IYUZEHlatanoprost (isopropyl ester)
16 more reported names
latanoprostum6Z5B6HVF6OXELPROSIsopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoateT-2345CHEBI:6384propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoateT2345XALACOM COMPONENT LATANOPROSTpropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoateLatanoprost PF5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-Monopostisopropyl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoatepropan-2-yl (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoatepropan-2-yl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
External database identifiers

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match5311221

Attributed physical-property, hazard, environmental and use annotations.

  • Note: This chemical does not meet GHS hazard criteria for 0.7% (1 of 145) of reports. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H300 (63.4%): Fatal if swallowed [Danger Acute toxicity, oral]; H301 (11%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (62.1%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 145 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 1 of 145 reports by companies.; There are 15 notifications provided by 144 of 145 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Toxicity Summary: Researchers found no carcinogenesis or mutagenesis with latanoprost, and the drug did not affect fertility in animal studies. However, latanoprost was noted to cause a chromosomal aberration in treated human lymphocytes. Intravenous infusion of 3 μg/kg of latanoprost in healthy volunteers produced plasma concentrations 200 times higher than during clinical treatment with latanoprost ophthalmic solution, and researchers identified no ADR. There is no evidence to establish a correlation between latanoprost administration and ocular or cutaneous melanoma.; Intravenous infusion of 5.5 to 10 μg/kg resulted in fatigue, sweating, dizziness, nausea, and abdominal pain. According to the manufacturer's labeling, treatment should be symptomatic if there is an overdosage with latanoprost ophthalmic solution. Source: StatPearls
  • Uses: Use (kg) in USA (2002): 1; Consumption (g per capita) in the USA (2002): 3.3e-06; Calculated removal (%): 100 Source: NORMAN Suspect List Exchange

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 155206-00-1
CAS 155206-00-1PubChem CID 5311027

Bimatoprost

IUPAC name
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
Molecular formula
C25H37NO4
Molecular weight
415.6 g/mol
Exact mass
415.27225866 Da
XLogP3
2.8
Topological polar surface area
89.8 Ų
Hydrogen-bond donors
4
Hydrogen-bond acceptors
4
Covalent units
1
Defined stereocentres
5

Also known as

LumiganLatisseAGN 192024ProstamideAGN-192024bimatoprostumDURYSTA(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
16 more reported names
CHEBI:51230GANFORT COMPONENT BIMATOPROST5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((E,3S)-3-hydroxy-5-phenylpent-1-enyl)cyclopentyl)-N-ethylhept-5-enamide(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide192024, AGNRefChem:54542S01EE035-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide(E)-7-[3,5-dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-UNII-QXS94885MZ
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 157283-66-4
CAS 157283-66-4PubChem CID 59938277

Isopropyl Cloprostenate

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
Molecular formula
C25H35ClO6
Molecular weight
467.0 g/mol
Exact mass
466.2122165 Da
XLogP3
3.8
Topological polar surface area
96.2 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
6
Covalent units
1
Defined stereocentres
5

Also known as

Cloprostenol isopropyl esterIsopropyl cloprostenolUNII-765298537GCPG-6112955-Heptenoic acid, 7-((1R,2R,3R,5S)-2-((1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl)-3,5-dihydroxycyclopentyl)-, 1-methylethyl ester, (5Z)-5-Heptenoic acid, 7-((1R,2R,3R,5S)-2-((1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, 1-methylethyl ester, (5Z)-CPG-6112-955-Heptenoic acid, 7-(2-(4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, 1-methylethyl ester, (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-
16 more reported names
5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5Z)-RefChem:149814ISOPROPYL CLOPROSTENATE [INCI]5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5Z)-(9CI)682-025-2(+)-Cloprostenol isopropyl esterisopropyl (Z)-7-((1R,2R,3R,5S)-2-((R,E)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate(+)-16-m-chlorophenoxy tetranor Prostaglandin F2alpha isopropyl esterISOPROPYL CLOPROSTENATC25H35ClO6D-cloprostenol isopropyl ester(+)-CloprostenolisopropylesterMSK2978CPG 6112-95HY-100571CS-0019712

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 157283-68-6
CAS 157283-68-6PubChem CID 5282226

Travoprost

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
Molecular formula
C26H35F3O6
Molecular weight
500.5 g/mol
Exact mass
500.23857332 Da
XLogP3
4.1
Topological polar surface area
96.2 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
9
Covalent units
1
Defined stereocentres
5

Also known as

TravatanTravatan ZIzbaAL-6221AL6221Otx-tptravoprostumIDOSE TR
16 more reported names
WJ68R08KX9CHEBI:746859NSC-760366DUOTRAV COMPONENT TRAVOPROSTpropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate5-Heptenoic acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (5Z)-isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoatepropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoateZ, TravatanAL 6221ISOPROPYL (Z)-7-((1R,2R,3R,5S)-3,5-DIHYDROXY-2-((1E,3R)-3-HYDROXY-4-((alpha,alpha,alpha-TRIFLUORO-M-TOLYL)OXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOATEpropan-2-yl (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoateTravoprost OphthalmicTravoprost IntracameralRefChem:56256Travoprost (Isomer Free)
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 209860-87-7
CAS 209860-87-7PubChem CID 9868491

Tafluprost

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
Molecular formula
C25H34F2O5
Molecular weight
452.5 g/mol
Exact mass
452.23743050 Da
XLogP3
4.5
Topological polar surface area
76.0 Ų
Hydrogen-bond donors
2
Hydrogen-bond acceptors
7
Covalent units
1
Defined stereocentres
4

Also known as

AFP-168TaflotanZioptanSaflutanMK-24521O6WQ6T7G3CHEBI:66899MK2452
16 more reported names
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hept-5-enoatetafluprostumtafluprost opthalmic5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5Z)-ISOPROPYL (5Z)-7-((1R,2R,3R,5S)-2-((1E)-3,3-DIFLUORO-4-PHENOXYBUT-1-ENYL)-3,5-DIHYDROXYCYCLOPENTYL)HEPT-5-ENOATEIsopropyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl}hept-5-enoatepropan-2-yl (5Z)-7-((1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoatepropan-2-yl (Z)-7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-(phenoxy)but-1-enyl)-3,5-dihydroxycyclopentyl)hept-5-enoatepropan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-(phenoxy)but-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoateTafluprost OphthalmicRefChem:57842S01EE055-Heptenoic acid, 7-((1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl)-3,5-dihydroxycyclopentyl)-, 1-methylethyl ester, (5Z)-1-methylethyl (5Z)-7-((1R,2R, 3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy-1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate(Z)-isopropyl 7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoateC25H34F2O5
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 35121-78-9
CAS 35121-78-9PubChem CID 5282411

Prostacyclin

IUPAC name
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
Molecular formula
C20H32O5
Molecular weight
352.5 g/mol
Exact mass
352.22497412 Da
XLogP3
2.9
Topological polar surface area
87.0 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
5

Also known as

epoprostenolprostaglandin I2PGI2VasocyclinProstaglandin XEpoprostenolumACT-385781ADCR9Z582X0
16 more reported names
U-53217(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acidU-53,217CHEBI:155526,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoic acidEpoprostanol(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoateProsta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-Prostaglandin I(2)epoprostenolo(5Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((E,3S)-3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta(b)furan-2-ylidene)pentanoic acid(5Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((E,3S)-3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta(d)furan-2-ylidene)pentanoic acid(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]pentanoic acidRefChem:57239B01AC09Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 363-24-6
CAS 363-24-6PubChem CID 5280360

Prostaglandin E2

IUPAC name
(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
Molecular formula
C20H32O5
Molecular weight
352.5 g/mol
Exact mass
352.22497412 Da
XLogP3
2.8
Topological polar surface area
94.8 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
4

Also known as

DinoprostonePGE2Prostin E2PrepidilCervidilMinprostin E2PropessMinprositin E2
16 more reported names
DinoprostonDinoprostonumCerviprostDinoprostonaEnzaprost ECerviprimeProstenonePGE2alphaU-12062(5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acidProstaglandin E2alpha(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acidU 12062K7Q1JQR04MProstaglandin E(2)(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 40665-92-7
CAS 40665-92-7PubChem CID 5311053

Cloprostenol

IUPAC name
(Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid
Molecular formula
C22H29ClO6
Molecular weight
424.9 g/mol
Exact mass
424.1652663 Da
XLogP3
2.7
Topological polar surface area
107.0 Ų
Hydrogen-bond donors
4
Hydrogen-bond acceptors
6
Covalent units
1
Defined stereocentres
5

Also known as

CloprostenolumOestrophaneEstrofanEstrophanEstrophaneOestrophan5-Heptenoic acid, 7-((1R,2R,3R,5S)-2-((1E,3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, (5Z)-rel-(5Z)-7-((1R,2R,3R,5S)-2-((1E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoic acid
16 more reported names
(5Z)-7-{(1R,2R,3R,5S)-2-[(1E,3R)-4-(3-Chlorophenoxy)-3-hydroxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoic acid(Z)-7-((1R,2R,3R,5S)-2-((E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl)-3,5-dihydroxycyclopentyl)hept-5-enoic acidSodium, CloprostenolRefChem:56481Cloprostenol Monosodium SaltMonosodium Salt, CloprostenolSalt, Cloprostenol MonosodiumICI80,966ICI 80,966(Z)-7-((1R*,2R*,3R*,5S*)-2-((E)-(3R*)-4-(3-Chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptensaeure255-028-8(+)-CloprostenolDalmazinR-CloprostenolDalmaprost DD-Cloprostenol
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 40666-16-8
CAS 40666-16-8PubChem CID 5311100

Fluprostenol

IUPAC name
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic acid
Molecular formula
C23H29F3O6
Molecular weight
458.5 g/mol
Exact mass
458.19162313 Da
XLogP3
2.9
Topological polar surface area
107.0 Ų
Hydrogen-bond donors
4
Hydrogen-bond acceptors
9
Covalent units
1
Defined stereocentres
5

Also known as

Fluprostenolumtravoprost free acidFluoprostenolICI 81,008358S7VUE5NCHEBI:60782ICI-80008 FREE ACIDICI 80,008 FREE ACID
16 more reported names
ICI 81008ICI-81008rac-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoic acid(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acidrac-(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)cyclopentyl)hept-5-enoic acidRefChem:921725255-029-3(+)-fluprostenoltravoprost acidFluprostenol, (+)-EINECS 255-029-3(+/-)-FluprostenolMEH3MCE8X1AL-58485-Heptenoic acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-buten-1-yl)cyclopentyl)-, (5Z)-C23H29F3O6
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 59122-46-2
CAS 59122-46-2PubChem CID 5282381

Misoprostol

IUPAC name
methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
Molecular formula
C22H38O5
Molecular weight
382.5 g/mol
Exact mass
382.27192431 Da
XLogP3
3.7
Topological polar surface area
83.8 Ų
Hydrogen-bond donors
2
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
3

Also known as

CytotecMisoprostolumSC-29333SC 293330E43V0BB57ARTHROTEC COMPONENT MISOPROSTOLmethyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oatemethyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate
16 more reported names
Apo MisoprostolProst-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13E)-misoprostoloMysodelleTopogyneNovo MisoprostolMisoprostol 1%methyl 7-((1R,2R,3R)-3-hydroxy-2-((1E)-4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl)heptanoateRefChem:55654Misoprostol 1% DispersionCHEBI:63610A02BB01G02AD06SC 30249664-288-5Isprelor
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 745-65-3
CAS 745-65-3PubChem CID 5280723

Alprostadil

IUPAC name
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
Molecular formula
C20H34O5
Molecular weight
354.5 g/mol
Exact mass
354.24062418 Da
XLogP3
3.2
Topological polar surface area
94.8 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
4

Also known as

Prostaglandin E1PGE1CaverjectEdexMuseAlprostadilumBefarProstin VR Pediatric
16 more reported names
VitarosPrinkPGE-1Prostavasin(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acidCaverject ImpulsePGE1alphaLipo PGE1Prostaglandin E1alpha11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoateU-101369-oxo-11R,15S-dihydroxy-13E-prostaenoic acidF5TD010360U-10,136CHEBI:15544
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

PubChem 2D chemical structure for CAS 81846-19-7
CAS 81846-19-7PubChem CID 6918140

Treprostinil

IUPAC name
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
Molecular formula
C23H34O5
Molecular weight
390.5 g/mol
Exact mass
390.24062418 Da
XLogP3
4.5
Topological polar surface area
87.0 Ų
Hydrogen-bond donors
3
Hydrogen-bond acceptors
5
Covalent units
1
Defined stereocentres
5

Also known as

UniprostRumodolinTyvasoUT-15LRX-15treprostinilo15AU81treprostinilum
16 more reported names
Tyvaso dpiRUM6K67ESG15-AU-81CHEBI:50861L-606((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate2-{[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta[b]naphthalen-5-yl]oxy}acetic acid({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acidAcetic acid, ((2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-(3-hydroxyoctyl)-1H-benz(f)inden-5-yl)oxy)-, (1R-(1alpha(S*),2beta,3aalpha,9aalpha))-trepostinil sodium(((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta(b)naphthalen-5-yl)oxy)acetic acid[(1R,2R,3aS,9aS)-2-Hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent[b]naphthalen-5-yl]oxy]acetate2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta(b)naphthalen-5-yl)oxy)acetic acid2-(((2R,3R,3aS,9aS)-2-hydroxy-3-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta(g)naphthalen-8-yl)oxy)acetic acid2-[[(2R,3R,3aS,9aS)-2-hydroxy-3-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-8-yl]oxy]acetic acidRefChem:56257
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity

US EPA CompTox CTX APIs

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity

Continue the compliance check

1. Confirm identity

Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.

2. Review restrictions

Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.

3. Verify the formula

Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.

Screen in a formulaOpen standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision